Chris Bond

Chris Bond

Company: Notch Therapeutics

Job title: Senior Vice President Pre-Clinical & Translational Sciences


Arming Cell Therapies to Override Immunosupressive Mechanisms to Penetrate Tumors 4:00 pm

Weaponizing cell therapies with armor cytokines, antibodies or co-stimulatory ligands to protect immunosuppression Discussing the impact of defence armoring vs. offensive armoring on different tumor and indications Targeting the specific immunosuppressive mechanisms of individual tumor types for personalized treatmentRead more

day: Day 1 - Track A - Post Lunch

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.